Clinical data | |
---|---|
Trade names | Voydeya |
Other names | ACH-4471 |
Routes of administration | By mouth |
Drug class | Complement factor D inhibitor |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
ECHA InfoCard | 100.398.865 |
Chemical and physical data | |
Formula | C6H3BrFN7O3 |
Molar mass | 320.038 g·mol−1 |
3D model (JSmol) | |
| |
|
Danicopan, sold under the brand name Voydeya, is a medication used for the treatment of paroxysmal nocturnal hemoglobinuria.[1] It is a complement inhibitor which reversibly binds to factor D to prevent alternative pathway-mediated hemolysis and deposition of complement C3 proteins on red blood cells.[1]
Danicopan was approved for medical use in Japan in January 2024.[2]
In February 2024, the Committee for Medicinal Products for Human Use of the EMA adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Voydeya, intended as add-on therapy to ravulizumab or eculizumab for the treatment of residual hemolytic anemia in adults with paroxysmal nocturnal hemoglobinuria (PNH).[1][3] The applicant for this medicinal product is Alexion Europe.[1]
Danicopan is the international nonproprietary name.[4]